Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: Implications for residual disease monitoring

Leukemia

Volumn 23, Issue 5, 2009, Pages 944-951

  Zaliova, M ^a   Fronkova, E ^a   Krejcikova, K ^a   Muzikova, K ^a   Mejstrikova, E ^a   Stary, J ^a   Trka, J ^a   Zuna, J ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS;

EID: 67349165085     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.386     Document Type: Article

References (47)

1. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R et al. Incidence and clinical outcome of children with BCR/ ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996; 10 957-963.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
3. Suryanarayan K, Hunger SP, Kohler S, Carroll AJ, Crist W, Link MP et al. Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood 1991; 77: 324-330.
4. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
5. Fletcher JA, Lynch EA, Kimball VM, Donnelly M, Tantravahi R, Sallan SE. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991; 77: 435-439.
6. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group. Cancer 1998; 83: 2030-2039.
7. Cazzaniga G, Lanciotti M, Rossi V, Di Martino D, Arico M, Valsecchi MG et al. Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol 2002; 119: 445-453.
8. Ribeiro RC, Broniscer A, Rivera GK, Hancock ML, Raimondi SC, Sandlund JT et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: Durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia 1997; 11: 1493-1496.
9. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998; 92 (8): 2730-2741.
10. Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000; 14: 1939-1943.
11. Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358: 1239-1241.
12. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95: 790-794.
13. Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 93-100.
14. van der Velden VH, Joosten SA, Willemse MJ, van Wering ER, Lankester AW, van Dongen JJ et al. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia 2001; 15: 1485-1487.
15. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352 1731-1738.
16. Krejci O, Prouzova Z, Horvath O, Trka J, Hrusak O. Cutting edge: TCR delta gene is frequently rearranged in adult B lymphocytes. J Immunol 2003; 171: 524-527.
17. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611.
18. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
19. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONIERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118.
20. Baruchel A, Cayuela JM, MacIntyre E, Berger R, Sigaux F. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: Implication for a general strategy of minimal residual disease detection. Br J Haematol 1995; 90: 85-93.
21. Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJ. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-2247.
22. Steward CG, Goulden NJ, Katz F, Baines D, Martin PG, Langlands K et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994; 83: 1355-1362.
23. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002; 99: 2315-2323.
24. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007; 21: 622-626.
25. Fronkova E, Madzo J, Zuna J, Reznickova L, Muzikova K, Hrusak O et al TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL. Leukemia 2005; 19: 1296-1297.
26. Madzo J, Zuna J, Muzikova K, Kalinova M, Krejci O, Hrusak O et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: Prospective real-time quantitative reverse transcriptasepolymerase chain reaction study. Cancer 2003; 97: 105-113.
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
29. Bruggemann M, van der Velden VH, Raff T, Droese J, Ritgen M, Pott C et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 709-719.
30. Langerak AW, Wolvers-Tettero IL, van Gastel-Mol EJ, Oud ME, van Dongen JJ. Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood 2001; 98 2456-2465.
31. van der Velden VH, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJ. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 2002; 16: 1372-1380.
32. van der Velden VH, Willemse MJ, van der Schoot CE, Hahlen K, van Wering ER, van Dongen JJ. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002; 16: 928-936.
33. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426-1435.
34. Pongers Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.
35. Yokota H, Tsuno NH, Tanaka Y, Fukui T, Kitamura K, Hirai H et al. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia 2002; 16: 1167-1175.
36. Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol 2000; 79: 424-431.
37. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371-2378.
38. van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996; 87: 5213-5217.
39. Fuster JL, Bermudez M, Galera A, Llinares ME, Calle D, Ortuno FJ. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2007; 92: 1723-1724.
40. Dow LW, Tachibana N, Raimondi SC, Lauer SJ, Witte ON, Clark SS. Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q 11 variants. Blood 1989; 73: 1291-1297.
41. Estrov Z, Talpaz M, Kantarjian HM, Zipf TF, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res 1993; 53: 3289-3293.
42. Primo D, Sanchez ML, Espinosa AB, Tabernero MD, Rasillo A, Sayagues JM et al. Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases. Br J Haematol 2006; 132: 736-739.
43. Secker-Walker LM, Cooke HM, Browett PJ, Shippey CA, Norton JD, Coustan-Smith E et al. Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia. Blood 1988; 72: 784-791.
44. Schenk TM, Keyhani A, Bottcher S, Kliche KO, Goodacre A, Guo JQ et al Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 1998; 12: 666-674.
45. Tachibana N, Raimondi SC, Lauer SJ, Sartain P, Dow LW. Evidence for a multipotential stem cell disease in some childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1987; 70: 1458-1461.
46. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-935.
47. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993; 92: 1925-1939.